The chronic kidney disease treatment market valued for $31.98 Billion in 2022 and is estimated to reach $47.90 Billion by 2032, exhibiting a CAGR of 4% from 2023 to 2032.
Chronic Kidney Disease (CKD) treatment refers to a range of medical interventions and strategies aimed at managing and slowing the progression of kidney damage and its associated complications. CKD is a progressive condition where the kidneys gradually lose their ability to filter waste products and excess fluids from the blood. The goals of CKD treatment Include preserving kidney function, controlling symptoms, preventing or managing complications, and improving the overall quality of life for individuals with CKD.
Treatment approaches may Include lifestyle modifications (such as dietary changes and regular physical activity), medications to control blood pressure and manage underlying conditions, interventions to address complications like anemia or bone disease, and in advanced stages, renal replacement therapies such as dialysis or kidney transplantation. The treatment plan is tailored to the individual's stage of CKD, underlying causes, comorbidities, and overall health status. Regular monitoring, close collaboration with healthcare providers, and adherence to the treatment plan are essential for optimizing outcomes and maintaining kidney health in individuals with CKD.
The Increasing prevalence of CKD is a significant driver of the CKD treatment market. The global burden of CKD has been steadily rising due to various factors, Including the aging population, the growing prevalence of risk factors such as diabetes and hypertension, and improved awareness and diagnosis. For instance, the aging population is a major contributing factor to the Increasing prevalence of CKD. As people age, the risk of developing CKD tends to Increase. According to the World Health Organization (WHO) in 2022, the global population aged 60 and above is expected to reach 2 billion by 2050, with a significant impact on the prevalence of age-related diseases, Including CKD.
Furthermore, the rising Incidence of risk factors like diabetes and hypertension has fueled the CKD epidemic. Diabetes, in particular, is a leading cause of CKD. The International Diabetes Federation in 2021, estimates that approximately 537 million adults were living with diabetes, and this number is projected to rise to 643 million by 2030 and 783 million by 2045. Thus, the prevailing cases, that directly translate to a higher risk of CKD development are anticipated to drive the market growth.
In addition, Increase in alcohol consumption, rise in the number of diagnostic tests for kidney diseases, surge in obese population, rise in R&D activities for launch of novel drugs and improvement in the existing drugs, and emerging technology in developing economies are positively impacting the growth of the chronic kidney disease treatment market.
However, factors that hinder the market growth Include the high cost of treatment for chronic kidney disease. Further, limited access to healthcare and inadequate healthcare infrastructure in certain regions can hinder the timely diagnosis and management of CKD. Thus, the aforementioned factors negatively impact market growth.
Moreover, the rise in the number of approvals from government regulatory agencies is creating lucrative opportunities for the CKD treatment market. For instance, in September 2022, AstraZeneca, a global leading life science company, received approval in China for Forxiga, to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D). In addition, the Increase in investment in R&D activities Increases the demand for efficient treatments, thereby providing lucrative opportunities for market growth.
The chronic kidney disease treatment market is segmented on the basis of treatment, end user, and region. On the basis of treatment, the market is classified into drugs and dialysis. The drugs is further categories into ACE Inhibitors, Erythropoietic Stimulating agents, Diuretics, and Other (phosphate binder, beta blockers, calcium channel blockers) and the dialiysis is further categorised into equipment and consumables. As per end user the market is segmented into Hospitals, Dialysis Centers and others (homecare and research and academic institutes). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global chronic kidney disease treatment market are AstraZeneca plc, Pfizer Inc. Johnson & Johnson, F. Hoffmann-La Roche Ltd., Baxter International Inc., Becton, Dickinson and Company, B. Braun SE, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Fresenius SE and Co. KGaA. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.
Chronic Kidney Disease (CKD) treatment refers to a range of medical interventions and strategies aimed at managing and slowing the progression of kidney damage and its associated complications. CKD is a progressive condition where the kidneys gradually lose their ability to filter waste products and excess fluids from the blood. The goals of CKD treatment Include preserving kidney function, controlling symptoms, preventing or managing complications, and improving the overall quality of life for individuals with CKD.
Treatment approaches may Include lifestyle modifications (such as dietary changes and regular physical activity), medications to control blood pressure and manage underlying conditions, interventions to address complications like anemia or bone disease, and in advanced stages, renal replacement therapies such as dialysis or kidney transplantation. The treatment plan is tailored to the individual's stage of CKD, underlying causes, comorbidities, and overall health status. Regular monitoring, close collaboration with healthcare providers, and adherence to the treatment plan are essential for optimizing outcomes and maintaining kidney health in individuals with CKD.
The Increasing prevalence of CKD is a significant driver of the CKD treatment market. The global burden of CKD has been steadily rising due to various factors, Including the aging population, the growing prevalence of risk factors such as diabetes and hypertension, and improved awareness and diagnosis. For instance, the aging population is a major contributing factor to the Increasing prevalence of CKD. As people age, the risk of developing CKD tends to Increase. According to the World Health Organization (WHO) in 2022, the global population aged 60 and above is expected to reach 2 billion by 2050, with a significant impact on the prevalence of age-related diseases, Including CKD.
Furthermore, the rising Incidence of risk factors like diabetes and hypertension has fueled the CKD epidemic. Diabetes, in particular, is a leading cause of CKD. The International Diabetes Federation in 2021, estimates that approximately 537 million adults were living with diabetes, and this number is projected to rise to 643 million by 2030 and 783 million by 2045. Thus, the prevailing cases, that directly translate to a higher risk of CKD development are anticipated to drive the market growth.
In addition, Increase in alcohol consumption, rise in the number of diagnostic tests for kidney diseases, surge in obese population, rise in R&D activities for launch of novel drugs and improvement in the existing drugs, and emerging technology in developing economies are positively impacting the growth of the chronic kidney disease treatment market.
However, factors that hinder the market growth Include the high cost of treatment for chronic kidney disease. Further, limited access to healthcare and inadequate healthcare infrastructure in certain regions can hinder the timely diagnosis and management of CKD. Thus, the aforementioned factors negatively impact market growth.
Moreover, the rise in the number of approvals from government regulatory agencies is creating lucrative opportunities for the CKD treatment market. For instance, in September 2022, AstraZeneca, a global leading life science company, received approval in China for Forxiga, to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D). In addition, the Increase in investment in R&D activities Increases the demand for efficient treatments, thereby providing lucrative opportunities for market growth.
The chronic kidney disease treatment market is segmented on the basis of treatment, end user, and region. On the basis of treatment, the market is classified into drugs and dialysis. The drugs is further categories into ACE Inhibitors, Erythropoietic Stimulating agents, Diuretics, and Other (phosphate binder, beta blockers, calcium channel blockers) and the dialiysis is further categorised into equipment and consumables. As per end user the market is segmented into Hospitals, Dialysis Centers and others (homecare and research and academic institutes). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global chronic kidney disease treatment market are AstraZeneca plc, Pfizer Inc. Johnson & Johnson, F. Hoffmann-La Roche Ltd., Baxter International Inc., Becton, Dickinson and Company, B. Braun SE, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Fresenius SE and Co. KGaA. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic kidney disease treatment market analysis from 2022 to 2032 to identify the prevailing chronic kidney disease treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the chronic kidney disease treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global chronic kidney disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By End User
- Hospital
- Dialysis Center
- Others
By Treatment
- Drugs
- Type
- Erythropoietic Stimulating agents
- Ace Inhibitors
- Diuretics
- Others
- Dialysis
- Type
- Equipment
- Consumables
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Pfizer Inc.
- Becton, Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- AstraZeneca plc
- B. Braun SE
- AbbVie Inc.
- Fresenius SE and Co. KGaA
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Baxter International Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT
CHAPTER 5: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER
CHAPTER 6: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY REGION
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Chronic kidney disease treatment Market,' The chronic kidney disease treatment market was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.Chronic kidney disease encompasses various conditions that inflict damage upon the kidneys, leading to a diminished capacity to effectively filter waste materials from the bloodstream, thereby compromising overall health. This prevalent ailment is frequently associated with the natural aging process, though it can affect individuals of any background. However, it exhibits a higher incidence among individuals of south Asian descent. The diagnosis of CKD primarily relies on blood and urine tests, which analyze the presence of elevated levels of specific substances in these bodily fluids. Such indicators serve as clear indications that the kidneys are not functioning optimally.
The market for CKD treatments is significantly influenced by the rising prevalence of CKD. Due to a number of variables, including an ageing population, an increase in the frequency of risk factors including diabetes and hypertension, as well as better knowledge and diagnosis. Further, the worldwide burden of CKD has been continuously rising. For instance, a significant cause in the rising prevalence of CKD is the ageing population. The likelihood of having CKD tends to rise with advancing age. By 2050, there will be 2 billion people in the world who are 60 years of age or older, according to the World Health Organisation (WHO), which will have a substantial impact on the prevalence of age-related disorders like CKD.
Additionally, rising alcohol consumption, an increase in kidney disease diagnostic tests, an increase in the population who are obese, an increase in R&D activities for the introduction of new drugs and improvements to existing drugs, and emerging technology in developing economies are all contributing to the market's expansion for the treatment of chronic kidney disease.
Further, Patients with chronic kidney disease (CKD) now have access to much better treatment choices owing to developments in dialysis technology and specialized drug research. Modern hemodialysis devices provide expanded control over dialysis parameters, user-friendly interfaces, and better monitoring systems. Larger pores on High-flux dialyzers also enable greater toxin and waste product clearance during treatment. Hemodiafiltration, which offers more effective solute removal, combines the hemodialysis and filtration principles. Patients now have more freedom and independence when receiving treatment. Thus, technological advancement and availability of portable and home dialysis equipment are driving the market growth.
Additionally, the governments of numerous emerging nations have begun concentrating on various projects for obtaining regulatory affairs approvals. For instance, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) recently approved a number of medications that have the potential to lower the risk of cardiovascular death, kidney failure, kidney function decline, and hospitalisation for heart failure in adults with chronic kidney disease who are at risk of disease progression. Further, In April 2021, FDA approved Farxiga (dapagliflozin) oral tablets. Similarly, In August 2021, AstraZeneca received an approval from the European Commission for treating chronic kidney disease in the European Union (EU). Therefore, it is projected that such prevalent situations, increased healthcare infrastructure, and expanding activities by governmental organisations would present profitable market opportunities.
Furthermore, the market also offers growth opportunities to the key players in the market. Many developing regions offer lucrative opportunities to key players of Chronic kidney diseases treatment market owing to high population base, increase in demand of efficient treatments with minimum side effects and rise healthcare spending. In addition, rise in disposable income and medical tourism fuels the growth of Chronic kidney diseases treatment market.
The global chronic kidney disease treatment market is segmented on the basis of treatment, end user, and region. On the basis of treatment, the market is classified into drugs and dialysis. The drugs is further categories into ACE Inhibitors, Erythropoietic Stimulating agents, Diuretics, and Other (phosphate binder, beta blockers, calcium channel blockers) and the dialiysis is further categorised into equipment and consumables. As per end user the market is segmented into Hospitals, Dialysis Centers and others (homecare and research and academic institutes). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include AstraZeneca plc, Pfizer Inc. Johnson & Johnson, F. Hoffmann-La Roche Ltd., Baxter International Inc., Becton, Dickinson and Company, B. Braun SE, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Fresenius SE and Co. KGaA. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.
Key Market Insights
- By treatment, the drugs segment dominated the market in 2022.
- By end user, the hospital segment dominated the market in 2022.
- By region, North America dominated the market in 2022. However, Asia-Pacific is expected to be the fastest growing region during the forecast period.
Companies Mentioned
- Pfizer Inc.
- Becton, Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- AstraZeneca plc
- B. Braun SE
- AbbVie Inc.
- Fresenius SE and Co. KGaA
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Baxter International Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
